TMS
Business Services · 11-50 Employees
View Company Info for Free
Overview
Phone Number
+81 423065087Website
www.tms-japan.co.jpRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About TMS
TMS Co., Ltd. is aprivately held, clinical stage biotechnology company based in Fuchu-shi, Tokyo. The company was founded in 2005 to develop therapeutics based on novel discoveries to modulate the fibrinolytic system, identified by a team of scientists at TokyoUniversityof Agriculture and Technology (TUAT), led by Dr.KeijiHasumi, Professor of the University and Chief Scientist of TMS.Explore more
TMS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TMS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if TMS is spiking on competitors!
Check if TMS has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on TMS recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at TMS
Product Launch: Get notified when TMS launches new products
Click to see if TMS had a recent Job posting/layoffs
Funding: Get notified immidiatlly once TMS has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
TMS, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined TMS as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
TMS is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TMS is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TMS.
TMS Tech Stack
A closer look at the technologies used by TMS
TMS News & Media
Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
CAMBRIDGE, Mass. and FUCHU-SHI, Tokyo, May 12, 2021 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and TMS Co., Ltd. announced today that Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen’s decision to acquire TMS-007 was based on positive data from a Phase 2a study. The study met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH) and demonstrated positive impacts on both bloodBiogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
CAMBRIDGE, Mass., June 07, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) announced today it has entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds. The agreement includes an upfront payment of $4 million and an additional $18 million payment if Biogen exercises its option, with up to $335 million in potential development and commercialization milestones as well as tiered royalties.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding TMS
Sign Up For FreeTo access detailed company insights
TMS Co., Ltd. is aprivately held, clinical stage biotechnology company based in Fuchu-shi, Tokyo. The company was founded in 2005 to develop therapeutics based on novel discoveries to modulate the fibrinolytic system, identified by a team of scientists at TokyoUniversityof Agriculture and Technology (TUAT), led by Dr.KeijiHasumi, Professor of the U... Read More
